Claims for Patent: 7,919,322

Summary for Patent: 7,919,322

Title:	Targeted deletions using retroelement-mediated placement of recombination sites
Abstract:	The present invention provides methods, nucleic acid constructs, and kits for selectively deleting a region of a nucleic acid sequence. Specifically, it utilizes retargeting retroelements to place site-specific recombination sites at targeted locations in the nucleic acid sequence. The region between the recombination sites is then deleted using a site-specific recombination system.
Inventor(s):	Spears; Melissa (St. Louis, MO), Davis; Greg (Webster Groves, MO), Kayser; Kevin (Chesterfield, MO)
Assignee:	Sigma-Aldrich Co. (St. Louis, MO)
Application Number:	11/391,972
Patent Claims:	1. A method for selectively deleting a region of a chromosome in a prokaryotic cell, the method comprising: a) providing to the prokaryotic cell a first nucleic acid encoding a first retargeted LI.LtrB intron and a first intron-encoded protein (IEP), wherein the first LI.LtrB intron and the first IEP sequences are under control of expression control sequences, wherein the first retargeted LI.LtrB intron comprises a first loxP site, and the first retargeted LI.LtrB intron inserts into a first targeted location in the chromosome; b) providing to the prokaryotic cell comprising the first nucleic acid, a second nucleic acid encoding a second retargeted LI.LtrB intron and a second IEP, wherein the LI.LtrB intron and the second IEP sequences are under control of expression control sequences, wherein the second retargeted LI.LtrB intron comprises a second loxP site, and the second retargeted LI.LtrB intron inserts into a second targeted location in the chromosome, wherein the first and the second loxP sites are in the same orientation; and c) providing to the prokaryotic cell comprising the first and the second nucleic acid a Cre recombinase that mediates recombination between the first and the second loxP sites to delete the region between the sites at the first and the second targeted locations in the chromosome of the prokaryotic cell. 2. The method of claim 1, wherein each of the first and the second retargeted LI.LtrB introns each further comprise a selectable marker flanked by a 5' end loxP site and a 3' end loxP site that are in the same orientation, wherein the 5' end and the 3' end loxP sites at first and the second targeted location are able to recombine thereby deleting the selectable marker and leaving one loxP site at each targeted location, the first loxP site at the first targeted location and the second loxP site at the second targeted location. 3. The method of claim 2, wherein the 5' end loxP site is a mutant site consisting of SEQ ID NO:2 and the 3' end loxP site is a wild-type site consisting of SEQ ID NO:1. 4. The method of claim 3, wherein each of the selectable markers is a retrotransposition-activated selectable marker (RAM). 5. The method of claim 4, wherein each RAM is a kanamycin resistance gene interrupted by a td group I intron (kan-RAM). 6. The method of claim 4, wherein the RAM at the first targeted location is removed by transient expression of the Cre recombinase prior to step (b). 7. The method of claim 2, wherein the selectable marker at the first targeted location is removed by transient expression of the Cre recombinase prior to step (b). 8. The method of claim 1, wherein the region selectively deleted from the chromosome is from about 0.1 kb to about 100 Mb in length. 9. The method of claim 1, wherein the region selectively deleted from the chromosome is from about 10 kb to about 1,000 kb in length. 10. The method of claim 1, wherein the prokaryotic cell is selected from the group consisting of Escherichia coli, Staphylococcus aureus, Lactococcus lactis, Shigella flexneri, Salmonella typhimurium, and Clostridium perfringens.

Details for Patent 7,919,322

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2039-02-26
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2039-02-26
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2039-02-26